 OKYO Pharma said it will work with US group AmbioPharm on the investigational new drug IND filing of dry eye disease DED treatment OK-101. A US filing is expected in the final quarter of 2022, OKYO reiterated today with a first human trial early scheduled for early in 2023 OKYO added this will be a phase 2 trial, skipping the normal phase 1 study, as the drug is administered topically. 